ISM1354

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676

The company nominated ISM0676, a prior GIPR antagonist, in January, which showed up to 31.3% weight loss in combination with Semaglutide in humanized mouse models. ISM1354 retains comparable weight-loss efficacy while delivering improved pharmacokinetic and safety profiles, addressing tolerability issues that have derailed rival GIPR programs industry-wide.